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Abstract
Empirical treatment of hospital-acquired pneumonia (HAP) has increas-
ingly been threatened by methicillin-resistant Staphylococcus aureus
Michael Kresken1,2
BarbaraKörber-Irrgang1(MRSA) and multidrug resistant Gram-negative pathogens. In contrast,
Martin Kaase3empirical treatment of community-acquired pneumonia (CAP) is primarily
Franziska Layer4impeded by antimicrobial-resistant pneumococci. Ceftobiprole, recently
approved for the treatment of HAP and CAP in Europe, is active against Yvonne Pfeifer4
a broad-spectrum of Gram-positive and Gram-negative pathogens, in-
Guido Werner4cludingMRSA and Pseudomonas aeruginosa. The objective of this study
Dieter Hafner5was to evaluate the susceptibility of ceftobiprole among 1,246 S. aureus,
Streptococcus pneumoniae, Enterobacteriaceae species and P. aeru-
ginosa isolated from respiratory tract and blood.
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“AntimicrobialIsolates were collected in 25 laboratories across Germany, Switzerland
and Austria. Minimum inhibitory concentrations (MICs) were determined Resistance” of the Paul
Ehrlich Society for
Chemotherapy
using the microdilution method according to the standard ISO 20776-
1:2006 and interpreted by the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) breakpoints. Two-thirds of the isolates
were obtained from respiratory specimens and one third from blood.
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GmbH, Rheinbach, Germany
There were 544 intensive care unit (ICU) isolates and 702 non-ICU
isolates. The share ofMRSA in S. aureuswas 16%. Among pneumococci,
2 University of Applied
Sciences, Cologne, Germany
18.5% showed reduced susceptibility to penicillin. An extended-spectrum
β-lactamase (ESBL) phenotype was confirmed for 18.4% of the Escheri-
chia coli and 16.7% of the Klebsiella pneumoniae isolates. Of the
P. aeruginosa isolates, 20.7% were ceftazidime-resistant.
3 Department of Medical
Microbiology, Ruhr-University
Bochum, GermanyMIC50/90 values of ceftobiprole for methicillin-susceptible S. aureus
(MSSA) and MRSA were 0.5/0.5 mg/L and 2/2 mg/L, respectively. All 4 Division of Nosocomial
Pathogens and Antibioticpneumococci were inhibited at 1 mg/L ceftobiprole. The activity of
ceftobiprole against E. coli and K. pneumoniae was similar to that of Resistance, Robert Koch
ceftriaxone, but ceftobiprole showed superior activity against Enterobac- Institute, Wernigerode,
Germanyteriaceae species known to produce chromosomally encoded AmpC-β-
lactamases. MIC50/90 values of ceftobiprole for ceftazidime-susceptible 5 Institute of Pharmacology
and Clinical Pharmacology,(4/16 mg/L) and ceftazidime-resistant P. aeruginosa (16/>32 mg/L)
were comparable to those of cefepime (4/8 mg/L and 32/>32 mg/L, Heinrich-Heine-University,
Düsseldorf, Germanyrespectively). These findings suggest that ceftobiprole may represent
a suitable option for the empirical treatment of HAP and CAP.
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Introduction
Community-acquired pneumonia (CAP) represents a fre-
quent infectious condition, with an incidence of 3–5 cases
per 1,000 persons per year [1]. Mortality of CAP is around
13–14% in hospitalized patients, as opposed to 1% in
ambulatory patients withmild CAP [2]. Themost common
microbial aetiology among hospitalized patients with CAP
is Streptococcus pneumoniae followed by atypical
pathogens, mixed aetiology and viruses [3]. Hospital-ac-
quired pneumonia (HAP) has been reported to be the
secondmost frequent healthcare-associated infection in
European acute-care hospitals [4]. Mortality associated
with HAP is limited in patients with reasonably good un-
derlying status when an appropriate therapy is started
immediately, but can be very high if initial antibiotic
therapy is inappropriate [5], [6]. Most common pathogens
in HAP are Staphylococcus aureus, Pseudomonas aeru-
ginosa, Acinetobacter baumannii and Enterobacteriaceae
(predominantly Klebsiella species, Escherichia coli, and
Enterobacter species), but S. pneumoniae may also be
a causative agent [4], [7].
Empirical treatment of HAP has increasingly been
threatened by the emergence and dissemination of
methicillin-resistant S. aureus (MRSA) and multidrug
resistant Gram-negative pathogens, while empirical
treatment of CAP should take the prevalence of antimi-
crobial resistance in pneumococci into account [7].
Ceftobiprole medocaril (Zevtera®), a new generation β-
lactam classified as group-5-cephalosporin by the Paul
Ehrlich Society for Chemotherapy [8], has recently been
approved in adults for the treatment of HAP, excluding
ventilator-associated pneumonia (VAP), and CAP in various
European countries, including Germany, Switzerland and
Austria. Ceftobiprole, which is the active moiety of the
pro-drug ceftobiprole medocaril, has been shown to have
a broad-spectrum of in vitro activity against Gram-positive
and Gram-negative pathogens, including MRSA, P. aeru-
ginosa and Enterobacteriaceae (except Proteus vulgaris)
[9], [10]. The antibacterial spectrum of ceftobiprole is
based on its high affinity for essential penicillin-binding
proteins, including PBP2’ of MRSA, and its stability to-
wards many β-lactamases [10]. Isolates of Acinetobacter
spp., Stenotrophomonas maltophilia and extended-
spectrum β-lactamase-producing (ESBL) Enterobacteri-
aceae, however, are poor targets for therapy with the
drug, like othermarketed broad-spectrum cephalosporins
[9].
The objective of this study was to evaluate the compara-
tive in vitro activity of ceftobiprole against key pathogens
associated with HAP and CAP, i.e. S. aureus, S. pneumo-
niae, Enterobacteriaceae species and P. aeruginosa,
collected during a resistance surveillance study conducted
by the Paul Ehrlich Society in 2010.
Material and methods
Bacterial strains
Data of clinical isolates prospectively collected in 25 la-
boratories across Germany (n=21), Switzerland (n=3)
and Austria (n=1) was analysed. Only first isolates from
hospitalized patients recovered from respiratory tract and
blood were included.
Demographic data requested from each participating
laboratory included patients’ age and gender, the location
of the patient (i.e. medical department), type of ward
(intensive care unit [ICU] or non-ICU), specimen type, and
the collection date. Identification of the bacterial isolates
at the study site was performed using routine laboratory
procedures. Strains were shipped to a reference labora-
tory (Antiinfectives Intelligence, Rheinbach, Germany) for
organism identification confirmation and susceptibility
testing.
Identification and susceptibility testing
Identification of isolates sent to the reference laboratory
was confirmed to the species level by standard laboratory
methods and by matrix-assisted laser desorption ioniza-
tion-time of flight (MALDI-TOF) mass spectrometry (MALDI
Biotyper, Microflex, Bruker Daltonik GmbH, Bremen,
Germany).
Table 1: Minimum inhibitory concentration breakpoints for
ceftobiprole [12]
Minimum inhibitory concentrations (MICs) of ceftobiprole
and comparators were determined by the microdilution
method, using commerciallymanufactured panels (Merlin
Diagnostika GmbH, Bornheim-Hersel, Germany) with
geometric two-fold serial dilutions of each antimicrobial
agent and cation-adjusted Mueller-Hinton broth as nutri-
ent medium, according to the standard ISO 20776-
1:2006 [11]. MICs were interpreted by the European
Committee on Antimicrobial Susceptibility Testing
(EUCAST) species-related clinical breakpoints, if applicable
[12]. Breakpoints of ceftobiprole are displayed in Table 1.
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E. coli ATCC 25922, P. aeruginosa ATCC 27853, and
S. aureus ATCC 29213 were used as quality control (QC)
strains. The QC ranges of the MICs were those listed in
the document ISO 20776-1:2006 [11]. Inoculum density
was verified by manual counting of colony forming units
(CFUs) for all QC strains and 10% of the clinical isolates.
Gram-positive isolates which showed ceftobiprole MICs
above the respective EUCAST resistance breakpoint
(2 mg/L for S. aureus and 0.5 mg/L for S. pneumoniae)
were also tested for ceftobiprole susceptibility by an agar
gradient diffusion test (Etest®) according to themanufac-
turer’s instructions (bioMérieux, Marcy-L’Etoile, France).
Phenotypic and molecular detection of
extended-spectrum β-lactamases
Isolates of E. coli, Klebsiella pneumoniae, Klebsiella
oxytoca, and Proteus mirabilis with resistance to cefo-
taxime and/or ceftazidime (MIC >1mg/L) were screened
for ESBL production. The Clinical and Laboratory Stand-
ards Institute (CLSI) ESBL phenotypic confirmatory test
with cefotaxime ± clavulanic acid and ceftazidime ±
clavulanic acid was performed on all isolates of these
four speciesmeeting the screening criterion [13]. Isolates
with a confirmed ESBL phenotype were further character-
ized by PCR amplification and sequencing of β-lactamase
genes (blaTEM-like, blaSHV-like and blaCTX-M-1-2-8-9-25group) as described
previously [14].
Molecular detection of carbapenemases
Isolates showing MICs of meropenem >8 mg/L were
tested for the presence of carbapenemases. For car-
bapenemase detection in Enterobacteriaceae, amodified
Hodge test [13] and combined disk tests with EDTA and
boronic acid were performed in addition to PCRs for blaKPC,
blaOXA-48, blaVIM, blaIMP and blaNDM [15]. In P. aeruginosa, a
modified Hodge test on MacConkey agar, a combined
disk test with EDTA and PCRs for blaKPC, blaVIM, blaIMP and
blaNDM as well as for blaGES [16] were performed. All ampli-
cons were sequenced. If the phenotypic tests suggested
the presence of a carbapenemase, further PCRs for rarely
occurring carbapenemase genes such as GIM were per-
formed [17]. If negative, a microbiological bioassay was
performed similarly as described previously [18].
Typing of MRSA strains
MRSA isolates were characterized by amplifying and se-
quencing of the polymorphic X-region of the protein A
gene (spa) as described previously [19]. The resulting
spa types were assigned by using the Ridom StaphType
software (Ridom GmbH, Würzburg, Germany).
Data processing and statistical
evaluation
Data were processed using Microsoft Excel. Statistical
significance of differences in resistance rates was judged
by comparing 95% confidence intervals (95%CI). Intervals
were constructed using the Newcombe-Wilson method
without continuity correction. If a calculated resistance
rate did not fall within the CI of the comparator, a signifi-
cance of p<0.05 was assumed. No further statistical
analysis was performed, considering the descriptive
nature of the study.
Results
A total of 1,246 clinical isolates were analysed. Of these,
813 (65.2%) were recovered from respiratory specimens
and 433 (34.8%) from blood. 544 (43.7%) and 702
(56.3%) isolates were obtained from intensive care pa-
tients and patients on general wards, respectively. There
were 254 S. pneumoniae, 241 P. aeruginosa, 188
S. aureus, 179 E. coli, 108 K. pneumoniae, 71 Serratia
marcescens, 65 Enterobacter cloacae, 44 K. oxytoca,
29 P. mirabilis, 19 Enterobacter aerogenes, 13 Citrobac-
ter freundii, 11 Citrobacter koseri and 24 isolates of
other Enterobacteriaceae species. 588 (47.2%) isolates
were recovered from patients with hospital-acquired in-
fections and 283 (22.7%) isolates from patients with
community-acquired infections (unknown source for the
remaining patients). Almost two thirds of the isolates were
recovered from male patients. Isolates were predomi-
nantly obtained from patients aged 60–79 years (n=616,
49.4%), followed by those aged 40–59 years (n=267,
21.4%) and then those aged ≥80 years (n=167, 13.4%).
The median age was 66 years (range <1–100 years).
The MIC frequency distributions of ceftobiprole for the
organism groups tested are presented in Table 2. Data
on the antimicrobial activities of ceftobiprole in compar-
ison to other antimicrobial agents, as well as the percent-
age of susceptible, intermediate and resistant strains,
are displayed in Table 3.
In vitro activity of ceftobiprole against
Gram-positive isolates
Of the S. aureus isolates, 158 (84%) were methicillin-
susceptible S. aureus (MSSA) and 30 (16%) were MRSA.
spa typing revealed, that 16 of the 30 MRSA isolates
belonged to either spa type t003 (EMRSA-3; New York
clone; German designation, Rhine HesseMRSA [n=9]) or
t032 (EMRSA-15; German designation, Barnim MRSA
[n=7]). Ceftobiprole demonstrated good activity against
S. aureus, with MIC50/90 values of 0.5/0.5 mg/L and
2/2 mg/L for MSSA and MRSA isolates, respectively. All
MSSA isolates, and 27/30 (90.0%) of MRSA isolates,
were considered ceftobiprole-susceptible. MICs of the
three ceftobiprole-resistantMRSAwere 4mg/L, one dilu-
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Table 2: Distributions of ceftobiprole MICs for bacterial isolates collected from the respiratory tract or blood of hospitalized
patients
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Table 3: In vitro activity of ceftobiprole and comparators against clinical isolates of most frequent bacterial species collected
from the respiratory tract or blood of hospitalized patients
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(Continued)
Table 3: In vitro activity of ceftobiprole and comparators against clinical isolates of most frequent bacterial species collected
from the respiratory tract or blood of hospitalized patients
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Table 3: In vitro activity of ceftobiprole and comparators against clinical isolates of most frequent bacterial species collected
from the respiratory tract or blood of hospitalized patients
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tion step above the breakpoint of 2 mg/L, two and one
of which were associated with spa type t032 and t001
(ST228; Southern GermanMRSA), respectively. The three
ceftobiprole-resistant isolates, as well as two randomly
selected ceftobiprole-susceptible MRSA of t032 (MICs
2mg/L), were re-tested by an agar gradient diffusion test
(Etest®). Etest® MICs were 3 mg/L for the t001 isolate
and 1–1.5 mg/L for the t032 isolates. Resistance rates
to levofloxacin and erythromycin were 7.6% and 13.3%,
respectively, for MSSA isolates and 100% and 80%, re-
spectively, for MRSA isolates. All S. aureus isolates were
susceptible to vancomycin, linezolid and daptomycin.
Of the 254 S. pneumoniae isolates, 47 (18.5%) exhibited
reduced susceptibility to penicillin (PNSP, MIC
>0,063mg/L), however, none were found to be penicillin-
resistant. Ceftobiprole inhibited all isolates at 1 mg/L,
though three blood isolates (1.2%) exhibiting penicillin
MICs of 1–2mg/L were categorized as ceftobiprole-resis-
tant. When the Etest® was applied, however, the ceftobi-
prole MIC for each of the three blood isolates was
0.5 mg/L (susceptible category). The highest MIC of
ceftriaxone for PNSP was also 1 mg/L. Resistance to
erythromycin and levofloxacin was observed in 51 (20.1%)
and 5 (2%) isolates, respectively. All S. pneumoniae iso-
lates were susceptible to vancomycin and linezolid (data
not shown).
In vitro activity of ceftobiprole against
Gram-negative isolates
Fifty-nine (16.3%) of the tested Enterobacteriaceae iso-
lates showed an ESBL phenotype, which included
33 E. coli, 18 K. pneumoniae, 6 K. oxytoca and
2 P. mirabilis. Proportions of isolates showing the ESBL
phenotype were 18.4% (E. coli), 16.7% (K. pneumoniae),
13.6% (K. oxytoca) and 6.9% (P. mirabilis).
Among the 563 Enterobacteriaceae isolates, 432 (76.7%)
were considered ceftobiprole-susceptible. MIC50/90 values
of ceftobiprole for E. coli and K. pneumoniae isolates
were comparable to those of ceftriaxone, but ceftobiprole
was more active than ceftriaxone against isolates of En-
terobacteriaceae species known to produce chromo-
somally encoded AmpC-β-lactamases. The higher in vitro
activity of ceftobiprole against C. freundii, E. cloacae and
S. marcescens, however, did not result in a greater pro-
portion of ceftobiprole-susceptible isolates. MIC50/90 values
of ceftobiprole for 19 E. cloacae isolates exhibiting high-
level resistance to ceftriaxone (MICs ≥16 mg/L) were
4/>32 mg/L, as compared to 4/16 mg/L for cefepime,
but none of these isolates was classified as ceftobiprole-
susceptible. Like other broad-spectrum cephalosporins,
ceftobiprole showed poor activity against isolates with
an ESBL phenotype. Two out of the 59 E. coli isolates
with an ESBL phenotype, however, were ceftobiprole-
susceptible. One isolate was inhibited by 2 mg/L cefo-
taxime, whichwas lowered to ≤0.25mg/Lwhen clavulanic
acid was added; the other had a ceftazidime MIC of
16mg/L, which was lowered to 0.5mg/L in the presence
of clavulanic acid. Neither isolate harboured an enzyme
of the groups CTX-M-, TEM- or SHV-type. In contrast, five
ESBL-negative E. coli and four ESBL-negative K. pneumo-
niae were considered ceftobiprole-resistant (MICs of
0.5–2 mg/L). Of interest, all five ESBL-negative E. coli
and two out of the four ESBL-negative K. pneumoniae
were resistant to amoxicillin-clavulanic acid (MICs
>128 mg/L) and piperacillin-tazobactam (MICs
32–>64 mg/L).
For most Enterobacteriaceae species, susceptibility rates
of ceftobiprole were slightly lower than those of ceftriax-
one (differences not statistically significant), but the
susceptibility rate of ceftobiprole for E. aerogenes was
superior to ceftriaxone (p<0.05). On the contrary, K. oxy-
toca isolates were susceptible to ceftobiprole less often
than ceftriaxone (p<0.05).
Resistance to ciprofloxacin was frequently seen in E. coli
(40.8%) and varied between 2.8% (S. marcescens) and
19.4% (K. pneumoniae) in the other Enterobacteriaceae
species. Meropenem inhibited all Enterobacteriaceae
isolates at 1 mg/L except for two isolates, one isolate
each of E. cloacae (MIC 32 mg/L) and S. marcescens
(MIC 16 mg/L). The E. cloacae isolate produced the
metallo-β-lactamase (MBL) VIM-1, while no car-
bapenemase was detected in the S. marcescens isolate.
MICs of ceftobiprole for both isolates were >16 mg/L, as
expected.
Of the 241 P. aeruginosa isolates, 191 (79.3%) were
susceptible to ceftazidime. Susceptibility rates of cipro-
floxacin (68.0%), meropenem (71.0%), cefepime (74.7%),
and piperacillin-tazobactam (77.2%) were slightly lower
while susceptibility to gentamicin (86.7%) was more
widespread. A carbapenemase was detected in 14
(41.2%) of the 34 meropenem-resistant isolates (VIM-2
[n=7], VIM-1 [n=2], IMP-31 [n=2], GES-5 [n=1], GIM-1
[n=1], and IMP-7 [n=1]). MIC50/90 values of ceftobiprole
for ceftazidime-susceptible P. aeruginosa isolates
(4/16 mg/L) were comparable to those of cefepime
(4/8 mg/L), but both drugs showed poor activity against
ceftazidime-resistant isolates, as expected.
Discussion
S. aureus, P. aeruginosa and Enterobacteriaceae are
considered the most common causative agents of HAP
[4], [7], while S. pneumoniae is the leading aetiological
agent among hospitalized patients with CAP [3]. Ceftobi-
prole is a broad-spectrum cephalosporin which demon-
strated in vitro and in vivo activity against S. aureus (in-
cludingMRSA), S. pneumoniae, Enterobacteriaceae (non-
ESBL phenotype) and P. aeruginosa [9], [10], [20], [21],
[22], [23]. The current study examined the in vitro activity
of ceftobiprole against a collection of 1,246 respiratory
and blood isolates of S. aureus, S. pneumoniae, P. aeru-
ginosa and Enterobacteriaceae that were collected from
hospitalized patients in Germany, Switzerland and Austria
in 2010.
According to data of the Paul Ehrlich Society, the preva-
lence of MRSA rose from below 2% in 1990 to 17.9% in
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2001. Subsequently, the rate of MRSA showed only
marginal variations until 2010 (16.7%) [24]. ARS (Antibio-
tika-Resistenz-Surveillance) is a laboratory-based surveil-
lance system that continuously collects resistance data
from routine medical samples (currently 28 in-patient
and out-patient care laboratories) on clinically relevant
bacteria in Germany. The ARS data on MRSA prevalence
indicates a downward trend after 2010 (2008: 20.6%;
2009: 20.1%; 2010: 22.4%; 2011: 17.4%; 2012: 17.0%;
2013: 13.9% for blood isolates) [25].
More than 98% of the S. aureus isolates (including 90%
of MRSA isolates) in the current study were considered
ceftobiprole-susceptible. However, based on MIC50/90 val-
ues, MRSA isolates were four times less susceptible to
ceftobiprole thanMSSA (wild type) isolates, as previously
observed by others [9], [10], [20].
The SENTRY Antibiotic Surveillance Program in Europe,
comprisingmore than 60,000 clinical bacterial pathogens
isolated in Europe, Turkey, and Israel from 2005 to 2010,
observed susceptibility to ceftobiprole in >4,000 MRSA
isolates (98.3%) [9], while 100% susceptibility to ceftobi-
prole was observed for a collection of 232MRSA isolates
from hospital-associated patients across Canada [20].
In both studies, MIC50/90 values of ceftobiprole were
1/2 mg/L for MRSA, as compared to 2/2 mg/L in the
present study. In contrast, Hebeisen et al. reported
MIC50/90 values of 2/4 mg/L for MRSA isolates [10]. The
trend towards slightly elevated ceftobiprole MICs in the
present study may have facilitated the finding of three
ceftobiprole-resistantMRSA. All threeMRSA isolates were
inhibited at 4 mg/L ceftobiprole, two of which turned out
to be susceptible when the Etest® was used, leaving one
“true” ceftobiprole-resistantMRSA isolate remaining. The
mechanism of ceftobiprole resistance was not investi-
gated. The resistant isolate belonged to spa type t001
(ST228), harbouring the staphylococcal chromosomal
cassette mec (SCCmec) type I [26]. Farrell et al. found
SCCmec type I strains to be less susceptible to ceftobi-
prole (MIC50/90, 2/4 mg/L) than SCCmec type II–IV strains
(MIC50/90, 1/1–2/2 mg/L) [27]. All MRSA isolates in the
current study were considered ceftobiprole-susceptible
at the pharmacokinetic/pharmacodynamic (PK/PD)
breakpoint of 4mg/L, which corresponds to a ceftobiprole
dosage of 500mg as a 2-hour intravenous infusion every
8 h.
Ceftobiprole also demonstrated high potency against
S. pneumoniae, with 98.8% testing susceptible. Two
penicillin-intermediate isolates (MICs 1 mg/L) and one
penicillin-resistant isolate were considered ceftobiprole-
resistant (MIC 1 mg/L), though Etest® results revealed
MICs of 0.5 mg/L (susceptible category). Ceftobiprole
also demonstrated high potency against S. pneumoniae
isolates collected during the European SENTRY Antibiotic
Surveillance Program, with 99.3% of 4,443 S. pneu-
moniae isolates testing susceptible [9].
Based on MIC50/90 values, the activity of ceftobiprole
against Enterobacteriaceae was comparable to those of
ceftriaxone or cefepime and susceptibility rates ranged
between 75% and 90% for most species. K. oxytoca
isolates, however, were less often susceptible to ceftobi-
prole than ceftriaxone. We speculate that ceftobiprole is
a stronger substrate than ceftriaxone for the chromo-
somally encoded class A OXY β-lactamases of K. oxytoca
[28]. Furthermore, like other broad-spectrumcephalospor-
ins, ceftobiprole showed poor activity against ESBL-posi-
tive Enterobacteriaceae isolates. Based onMIC50/90 values,
the activity of ceftobiprole against Enterobacteriaceae
species known to produce chromosomally encoded AmpC-
producing β-lactamases resembled that of cefepime, but
because of the comparatively low breakpoint of resistance
set for ceftobiprole (>0.25mg/L as compared to >2mg/L
for cefepime) the resistance rates of ceftobiprole found
for E. cloacae, C. freundii, and S. marcescens were con-
siderably higher than those of cefepime.
The potency of ceftobiprole against P. aeruginosa was
comparable to ceftazidime and cefepime, as shown in
previous in vitro studies [9], [10], [20]; however, as
EUCAST has not set a species-related clinical breakpoint
for P. aeruginosa, we were not able to assess the rate of
ceftobiprole-susceptible isolates. At the target concentra-
tion of 4mg/L, susceptibility to ceftobiprole was achieved
in 58% of the P. aeruginosa isolates tested, which was
similar to the susceptibility rate (64.6%) found for 3,434
P. aeruginosa isolates in the European SENTRY Antibiotic
Surveillance Program [9].
Based on the spectrum of pathogens recovered from the
patients enrolled in the Phase 3 clinical trial of ceftobi-
prole medocaril versus ceftazidime plus linezolid for the
treatment of HAP [29], and the susceptibility data found
in this surveillance study, we predict that 80% of the mi-
crobiological aetiologies associated with HAP (excluding
VAP) would be ceftobiprole-susceptible (Table 4).
Identical coverage rates are predicted for piperacil-
lin/tazobactam and cefepime, while imipenem and
meropenem would cover almost 90% of the pathogen
spectrum.
In conclusion, the results of this surveillance study
demonstrate that ceftobiprole is active against key
pathogens associated with HAP and CAP in hospitalized
patients. Hence, ceftobiprole may represent a suitable
option for the empirical treatment of HAP and CAP, espe-
cially for cases in which both MRSA and Gram-negative
pathogens are suspected. One should be aware, however,
of the lack of activity of ceftobiprole against ESBL-produ-
cing strains. Furthermore, the addition of a combination
partner can be considered if the patient is at risk for a
P. aeruginosa infection as susceptibilities of this species
are difficult to predict [29].
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Erratum
The reference in Tab. 4 was corrected from [23] to [29].
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